Miami Law To Discuss Legal Issues Tied To Medical Breakthroughs At Global Business Forum


Miami Law will discuss the legal complexities resulting from scientific and medical advancements at this year's University of Miami Global Business Forum.

The Forum, organized by the University of Miami School of Business Administration, will take place on the Coral Gables campus Jan. 12-14. The event will bring together professionals from academia, business, government and a wide range of industries to discuss The Business of Health Care: Defining the Future.

On Friday, Jan. 14, Miami Law Professor Mary Coombs, who teaches and writes in the areas of law and medicine, will moderate a discussion by Gary E. Marchant, PH.D., J.D. from Arizona State University. Marchant is the Executive Director for the Center for Law and Science & Technology at ASU, as well as a Lincoln Professor of Emerging Technologies, Law and Ethics at the Sandra Day O'Connor College of Law.

Marchant will speak about Emerging Technologies and Health Care, an intriguing topic that will demonstrate how scientific breakthroughs pose legal, policy and ethical challenges relating to regulatory approval, reimbursement, intellectual property and liability.

Marchant explains that much of the focus in health care has been angled toward the technological and scientific obstacles, but now as those breakthroughs surface, the legal hurdles and impediments are also coming to light.

"It is essential that we look at these now," said Marchant, who added that there will be a greater need for professionals to steer the course. "There need to be lawyers who know how to handle these scientific issues."

This is the second year the University of Miami has held the Global Business Forum. In 2009, the event gathered more than 700 professionals.

The forum will feature panel discussions organized by schools and colleges across campus.

Event keynote speakers include University of Miami President Donna E. Shalala; Kathleen Sebelius, U.S. Secretary of Health and Human Services, and Margaret Hamburg, MD, Commissioner, U.S. Food and Drug Administration